Structure Therapeutics Inc. American Depositary Shares represent ownership interests in Structure Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for chronic metabolic and cardiopulmonary diseases with significant unmet medical needs. The company’s current programs center on medicines designed to target G protein-coupled receptors, a broad and important class of biological pathways involved in disease signaling. Its research pipeline includes candidates aimed at obesity and related metabolic conditions, as well as additional therapeutic areas within chronic disease management. Structure Therapeutics operates as a science-driven drug developer, combining discovery, preclinical work, and clinical-stage development to advance treatments intended for long-term use in specialized medical markets. The American Depositary Shares provide a U.S.-traded equity form for the company’s ordinary shares, giving market participants access to a biopharmaceutical business built around oral therapeutics and targeted receptor biology.
Website601 Gateway Boulevard
South San Francisco, CA, 94080
United States
Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share price return of 5.17% to US$36.81 came after a year-to-date share price decline of 45.96%. Meanwhile, the 1-year total shareholder return of 50.55% points to strong longer term momentum that has cooled...
Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist. The single-dose portion of a Phase 1/2a trial enrolled 31 healthy adults without obesity. Six participants receiving 10 milligrams recorded a mean 3.3% body-weight reduction at day 24. For investors, the attraction is measurable activity after one […]
Tipranks Press Release.
Investors talking about GPCR also mention
| # | Name | Attention |
|---|---|---|
| 1 | MTSR - Metsera, Inc. | —— |
| 2 | TERN - Terns Pharmaceuticals, Inc. | —— |
| 3 | Viking Therapeutics, Inc.VKTX | 0.18%0 |
| 4 | Madrigal Pharmaceuticals Inc.MDGL | 0%-0.02 |
| 5 | Abivax SAABVX | 0.01%-0.01 |
| 6 | Mineralys Therapeutics, Inc.MLYS | 0%+0 |
| 7 | Wave Life Sciences Ltd.WVE | 0%+0 |
| 8 | ETNB - 89bio, Inc. | —— |
| 9 | Janux Therapeutics, Inc.JANX | 0%0 |
| 10 | Revolution Medicines, Inc.RVMD | 0.01%-0.01 |
What share of all stock conversation is about GPCR?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% 0 | 0% +0 | 0% +0 |
Of the messages about GPCR that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 40% | 53.57% -32.69 | 81.77% +25.52 | 67.45% -11.82 | ||
| Bearish | 60% | 46.43% +32.69 | 18.23% -25.52 | 32.55% +11.82 |
Of the messages about GPCR that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 0% | 83.33% | 80.06% | 80.16% | ||
| Technical Analysis | 100% | 16.67% | 0.31% | 5.76% | ||
| Analysts | 0% | 0% | 19.63% | 10.12% | ||
| Controversies | 0% | 0% | 0% | 3.17% | ||
| Earnings | 0% | 0% | 0% | 0.09% | ||
| Macro | 0% | 0% | 0% | 0.7% |
Of the messages about GPCR, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 72.55% | 81.43% | 57.21% | ||
| Newcomers | 0% | 27.45% | 18.57% | 42.79% |